Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873377 | 1.00 | JAK2 (0.34) | JAK2JAK1SSTR1SSTR4BPTF | |
| SCHEMBL4764601 | 0.82 | TP53 (0.33) | HTR2AHTR2CHSP90AB1TOP2A | |
| SCHEMBL4764579 | 0.70 | DRD2 (0.34) | HTR2A | |
| SCHEMBL4766195 | 0.68 | DRD2 (0.52) | — | |
| SCHEMBL15011795 | 0.66 | JAK2 (0.39) | JAK2JAK1SSTR4HTR2AHTR2C | |
| SCHEMBL20689435 | 0.64 | SLC6A2 (0.42) | SSTR1SSTR4HTR2AHTR2CKCNH2 | |
| SCHEMBL20689429 | 0.64 | SLC6A2 (0.42) | SSTR1SSTR4HTR2AHTR2CKCNH2 | |
| SCHEMBL26116816 | 0.63 | DDB1 (0.33) | JAK2JAK1 | |
| SCHEMBL26117731 | 0.63 | DDB1 (0.33) | JAK2JAK1 | |
| SCHEMBL26116146 | 0.63 | DDB1 (0.33) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312211-A1 | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | SDHA, QDPR, PNKP | JAK2 3083/4885JAK1 3063/4885SSTR1 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.